After Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk has cut the price of weight ...

Novo Nordisk A/S is following in rival Eli Lilly & Co.’s footsteps by selling its hit weight-loss drug Wegovy directly to US ...

The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Few things have stirred up as much commotion in either the weight loss or pharmaceutical world as Ozempic and Wegovy. There's a good reason for that — these drugs have proven to be highly ...

Novo Nordisk said game on, as the Denmark-based drugmaker lowered prices on its obesity treatment Wegovy for those without insurance, and said it would deliver the drug to their homes. Tomi ...

Try eating at least one more serving of a fruit or vegetable every day if you are not getting at least five a ...

You may have done your research and settled on Wegovy for weight management or cardiovascular health. Now what? Telemedicine options might be your ticket to fulfill the prescription, deliver it ...

Wegovy (semaglutide) and Mounjaro (tirzepatide) are brand-name injections. Wegovy is prescribed for weight loss and to lower cardiovascular risks. Mounjaro is approved for type 2 diabetes ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

The FDA has declared that the shortage of popular weight-loss drugs, including Ozempic and Wegovy, is officially over.